Synkir-110, Autologous T Cells Transduced With Mesothelin Kir-Car
Cholangiocarcinoma Recurrent
Verismo TherapeuticsCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
92 Active assets in the Cholangiocarcinoma Recurrent cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Jonsson Comprehensive Cancer Center | Phase 3 | BB |
Eloxatin Jonsson Comprehensive Cancer Center | Phase 3 | BB |
Irinotecan Jonsson Comprehensive Cancer Center | Phase 3 | B |
ETOMIDATE Cheju Halla General Hospital | Phase 4 | B |
Docetaxel Merck Sharp & Dohme LLC | Phase 2 | B |
View all 50 →
Same molecule, other indications
Synkir-110, Autologous T Cells Transduced With Mesothelin Kir-Car is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →